ArticleFrontiers in oncology2019
MicroRNA-153 Decreases Tryptophan Catabolism and Inhibits Angiogenesis in Bladder Cancer by Targeting Indoleamine 2,3-Dioxygenase 1.
Article in Frontiers in oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 58 citations in OpenAlex.
- Immunometabolism: crosstalk with tumor metabolism and implications for cancer immunotherapy.Molecular cancer · 2025Review
- Tryptophan metabolism: From physiological functions to key roles and therapeutic targets in cancer (Review).Oncology reports · 2025Review
- Microbiome and bladder cancer: the role of probiotics in treatment.Future microbiology · 2025Review
- Integrated longitudinal multiomics study identifies immune programs associated with acute COVID-19 severity and mortality.The Journal of clinical investigation · 2024Observational
- Unveiling the Role of Tryptophan 2,3-Dioxygenase in the Angiogenic Process.Pharmaceuticals (Basel, Switzerland) · 2024Article
- The role of microbiota in tumorigenesis, progression and treatment of bladder cancer.Microbiome research reports · 2024Review
- Review
- An Overview of Angiogenesis in Bladder Cancer.Current oncology reports · 2023Review
- Indoleamine-2,3 dioxygenase: a fate-changer of the tumor microenvironment.Molecular biology reports · 2023Review
- Downregulation of miR‑7 and miR‑153 is involved inInternational journal of oncology · 2023Article
- Mir-153-3p Modulates the Breast Cancer Cells' Chemosensitivity to Doxorubicin by Targeting KIF20A.Cancers · 2023Article
- IDO promotes the proliferation and invasion of prostate cancer cells through KYNU.Genes & genomics · 2023Article
- Integrated Analysis of Metabolomics and Lipidomics in Plasma of T2DM Patients with Diabetic Retinopathy.Pharmaceutics · 2022Article
- Oxymatrine induces anti-tumor response in cervical cancer by modulating circ_0008460/miR-197-3p/ribonucleotide reductase subunit M2 (RRM2).Bioengineered · 2022Article
- The role of miR-153 and related upstream/downstream pathways in cancers: from a potential biomarker to treatment of tumor resistance and a therapeutic target.Medical oncology (Northwood, London, England) · 2022Review
- Occludin facilitates tumour angiogenesis in bladder cancer by regulating IL8/STAT3 through STAT4.Journal of cellular and molecular medicine · 2022Article
- Article
- Circ_0020123 enhances the cisplatin resistance in non-small cell lung cancer cells partly by sponging miR-140-3p to regulate homeobox B5 (HOXB5).Bioengineered · 2022Article
- Angioregulatory microRNAs in breast cancerJournal of advanced research · 2022Review
- A comprehensive review on miR-153: Mechanistic and controversial roles of miR-153 in tumorigenicity of cancer cells.Frontiers in oncology · 2022Review
Corrections and comments
- Erratum issued
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.